Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Gavreto (pralsetinib) is a targeted therapy designed to treat adults with specific types of thyroid cancer and non-small cell lung cancer (NSCLC) that are caused by abnormal rearranged during transfection (RET) genes. This breakthrough medication, approved by the FDA, operates as a kinase inhibitor, specifically targeting RET alterations that drive tumor growth in certain cancer patients. Gavreto is a beacon of hope for those with advanced or metastatic cancer, offering a tailored approach to combat these challenging conditions.
Before you buy Gavreto, it is crucial that you talk to your healthcare provider about potential side effects and Gavreto cost.
| Fact Table | |
|---|---|
| Formula | C27H32FN7O3 |
| License | FDA approved |
| Bioavailability | High (increases with a high-fat meal) |
| Legal status | Prescription Drugs |
| Chemical Name | Pralsetinib |
| Elimination half-life | 15 hours |
| Dosage (Strength) | 100 mg, 200 mg capsules |
| Pregnancy | Contraindicated; should not be used during pregnancy |
| Brands | Gavreto |
| Protein binding | 97% |
| PubChem CID | 135565884 |
| MedlinePlus | Not listed specifically for Gavreto |
| ChEBI | Not applicable |
| ATC code | Not available |
| DrugBank | DB15670 |
| KEGG | D11882 |
| Routes of administration | Oral |
Gavreto is administered orally and is available in capsule form. It is crucial to follow the prescription provided by your healthcare provider precisely. Typically, the recommended dose is 400 mg, taken once daily. The capsules must be taken whole with water and may be ingested either with or without food.
Active Ingredient: Pralsetinib.
If you experience signs of an allergic reaction such as rash, swelling, itching, or severe dizziness, seek medical attention immediately.
Inform your doctor about any pre-existing liver, kidney, or heart conditions, as Gavreto 100 mg may exacerbate certain health issues.
Gavreto can harm an unborn baby; avoid use if you are pregnant or planning to become pregnant.
High blood pressure can occur with Gavreto use. Regular monitoring of blood pressure is advised throughout treatment.
Gavreto can interact with various other medications, which can alter how it works or increase the risk of serious side effects. It is important to inform your healthcare provider about all medications you are currently taking, including:
Blood Thinners: Increased risk of bleeding.
Proton Pump Inhibitors (PPIs): May reduce the effectiveness of Gavreto.
Antibiotics and Antifungals: Some types can increase the concentration of Gavreto in the blood, leading to potential toxicity.
Herbal Products: Supplements such as St. John's Wort can decrease the effectiveness of Gavreto.
Avoid consuming grapefruit or grapefruit juice during your treatment with Gavreto, as it can increase blood levels of the medication.
While Gavreto has been proven effective for many patients, it can cause side effects. Some common side effects include fatigue, constipation, muscle and joint pain, and dry mouth.
What is Gavreto used for?
Gavreto (pralsetinib) is used to treat certain types of cancers that are caused by specific gene mutations or abnormalities. It is specifically indicated for the treatment of non-small cell lung cancer (NSCLC) with RET gene fusions, and for RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.
Is Gavreto immunotherapy?
No, Gavreto is not considered immunotherapy. Gavreto is a targeted therapy that works by inhibiting the activity of RET (rearranged during transfection) proteins that drive the growth of cancer cells.
Is Gavreto FDA approved?
Yes, Gavreto is FDA approved. The U.S. Food and Drug Administration (FDA) has approved Gavreto for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer.
What are the results of Gavreto?
Clinical trials have shown that Gavreto is effective in shrinking tumors and slowing disease progression in patients with RET fusion-positive NSCLC and RET-mutant or RET fusion-positive thyroid cancers. Response rates and duration of response vary, but many patients experience significant tumor reduction.
How does Gavreto work?
Gavreto works by inhibiting the RET kinase, a protein that is involved in the signaling pathways that promote cancer cell growth and survival. By blocking this protein, Gavreto can help stop the growth and spread of cancer cells.
What is the indication of Gavreto?
Gavreto is indicated for the treatment of adult patients with:
Is pralsetinib chemotherapy?
No, pralsetinib (Gavreto) is not chemotherapy. It is a targeted therapy that specifically targets and inhibits RET kinase, a protein involved in cancer cell growth. Chemotherapy, in contrast, works by killing rapidly dividing cells, but it is not as selective and affects both cancerous and healthy cells.
